Cargando…

Discovery of pre-therapy 2-deoxy-2-(18)F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients

PURPOSE: The aim of this multi-center study was to discover and validate radiomics classifiers as image-derived biomarkers for risk stratification of non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Pre-therapy PET scans from a total of 358 Stage I–III NSCLC patients scheduled for radiother...

Descripción completa

Detalles Bibliográficos
Autores principales: Arshad, Mubarik A., Thornton, Andrew, Lu, Haonan, Tam, Henry, Wallitt, Kathryn, Rodgers, Nicola, Scarsbrook, Andrew, McDermott, Garry, Cook, Gary J., Landau, David, Chua, Sue, O’Connor, Richard, Dickson, Jeanette, Power, Danielle A., Barwick, Tara D., Rockall, Andrea, Aboagye, Eric O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333728/
https://www.ncbi.nlm.nih.gov/pubmed/30173391
http://dx.doi.org/10.1007/s00259-018-4139-4
_version_ 1783387608909348864
author Arshad, Mubarik A.
Thornton, Andrew
Lu, Haonan
Tam, Henry
Wallitt, Kathryn
Rodgers, Nicola
Scarsbrook, Andrew
McDermott, Garry
Cook, Gary J.
Landau, David
Chua, Sue
O’Connor, Richard
Dickson, Jeanette
Power, Danielle A.
Barwick, Tara D.
Rockall, Andrea
Aboagye, Eric O.
author_facet Arshad, Mubarik A.
Thornton, Andrew
Lu, Haonan
Tam, Henry
Wallitt, Kathryn
Rodgers, Nicola
Scarsbrook, Andrew
McDermott, Garry
Cook, Gary J.
Landau, David
Chua, Sue
O’Connor, Richard
Dickson, Jeanette
Power, Danielle A.
Barwick, Tara D.
Rockall, Andrea
Aboagye, Eric O.
author_sort Arshad, Mubarik A.
collection PubMed
description PURPOSE: The aim of this multi-center study was to discover and validate radiomics classifiers as image-derived biomarkers for risk stratification of non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Pre-therapy PET scans from a total of 358 Stage I–III NSCLC patients scheduled for radiotherapy/chemo-radiotherapy acquired between October 2008 and December 2013 were included in this seven-institution study. A semi-automatic threshold method was used to segment the primary tumors. Radiomics predictive classifiers were derived from a training set of 133 scans using TexLAB v2. Least absolute shrinkage and selection operator (LASSO) regression analysis was used for data dimension reduction and radiomics feature vector (FV) discovery. Multivariable analysis was performed to establish the relationship between FV, stage and overall survival (OS). Performance of the optimal FV was tested in an independent validation set of 204 patients, and a further independent set of 21 (TESTI) patients. RESULTS: Of 358 patients, 249 died within the follow-up period [median 22 (range 0–85) months]. From each primary tumor, 665 three-dimensional radiomics features from each of seven gray levels were extracted. The most predictive feature vector discovered (FVX) was independent of known prognostic factors, such as stage and tumor volume, and of interest to multi-center studies, invariant to the type of PET/CT manufacturer. Using the median cut-off, FVX predicted a 14-month survival difference in the validation cohort (N = 204, p = 0.00465; HR = 1.61, 95% CI 1.16–2.24). In the TESTI cohort, a smaller cohort that presented with unusually poor survival of stage I cancers, FVX correctly indicated a lack of survival difference (N = 21, p = 0.501). In contrast to the radiomics classifier, clinically routine PET variables including SUV(max), SUV(mean) and SUV(peak) lacked any prognostic information. CONCLUSION: PET-based radiomics classifiers derived from routine pre-treatment imaging possess intrinsic prognostic information for risk stratification of NSCLC patients to radiotherapy/chemo-radiotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-018-4139-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6333728
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-63337282019-01-27 Discovery of pre-therapy 2-deoxy-2-(18)F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients Arshad, Mubarik A. Thornton, Andrew Lu, Haonan Tam, Henry Wallitt, Kathryn Rodgers, Nicola Scarsbrook, Andrew McDermott, Garry Cook, Gary J. Landau, David Chua, Sue O’Connor, Richard Dickson, Jeanette Power, Danielle A. Barwick, Tara D. Rockall, Andrea Aboagye, Eric O. Eur J Nucl Med Mol Imaging Original Article PURPOSE: The aim of this multi-center study was to discover and validate radiomics classifiers as image-derived biomarkers for risk stratification of non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Pre-therapy PET scans from a total of 358 Stage I–III NSCLC patients scheduled for radiotherapy/chemo-radiotherapy acquired between October 2008 and December 2013 were included in this seven-institution study. A semi-automatic threshold method was used to segment the primary tumors. Radiomics predictive classifiers were derived from a training set of 133 scans using TexLAB v2. Least absolute shrinkage and selection operator (LASSO) regression analysis was used for data dimension reduction and radiomics feature vector (FV) discovery. Multivariable analysis was performed to establish the relationship between FV, stage and overall survival (OS). Performance of the optimal FV was tested in an independent validation set of 204 patients, and a further independent set of 21 (TESTI) patients. RESULTS: Of 358 patients, 249 died within the follow-up period [median 22 (range 0–85) months]. From each primary tumor, 665 three-dimensional radiomics features from each of seven gray levels were extracted. The most predictive feature vector discovered (FVX) was independent of known prognostic factors, such as stage and tumor volume, and of interest to multi-center studies, invariant to the type of PET/CT manufacturer. Using the median cut-off, FVX predicted a 14-month survival difference in the validation cohort (N = 204, p = 0.00465; HR = 1.61, 95% CI 1.16–2.24). In the TESTI cohort, a smaller cohort that presented with unusually poor survival of stage I cancers, FVX correctly indicated a lack of survival difference (N = 21, p = 0.501). In contrast to the radiomics classifier, clinically routine PET variables including SUV(max), SUV(mean) and SUV(peak) lacked any prognostic information. CONCLUSION: PET-based radiomics classifiers derived from routine pre-treatment imaging possess intrinsic prognostic information for risk stratification of NSCLC patients to radiotherapy/chemo-radiotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-018-4139-4) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-09-01 2019 /pmc/articles/PMC6333728/ /pubmed/30173391 http://dx.doi.org/10.1007/s00259-018-4139-4 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Arshad, Mubarik A.
Thornton, Andrew
Lu, Haonan
Tam, Henry
Wallitt, Kathryn
Rodgers, Nicola
Scarsbrook, Andrew
McDermott, Garry
Cook, Gary J.
Landau, David
Chua, Sue
O’Connor, Richard
Dickson, Jeanette
Power, Danielle A.
Barwick, Tara D.
Rockall, Andrea
Aboagye, Eric O.
Discovery of pre-therapy 2-deoxy-2-(18)F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients
title Discovery of pre-therapy 2-deoxy-2-(18)F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients
title_full Discovery of pre-therapy 2-deoxy-2-(18)F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients
title_fullStr Discovery of pre-therapy 2-deoxy-2-(18)F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients
title_full_unstemmed Discovery of pre-therapy 2-deoxy-2-(18)F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients
title_short Discovery of pre-therapy 2-deoxy-2-(18)F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients
title_sort discovery of pre-therapy 2-deoxy-2-(18)f-fluoro-d-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333728/
https://www.ncbi.nlm.nih.gov/pubmed/30173391
http://dx.doi.org/10.1007/s00259-018-4139-4
work_keys_str_mv AT arshadmubarika discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT thorntonandrew discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT luhaonan discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT tamhenry discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT wallittkathryn discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT rodgersnicola discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT scarsbrookandrew discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT mcdermottgarry discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT cookgaryj discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT landaudavid discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT chuasue discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT oconnorrichard discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT dicksonjeanette discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT powerdaniellea discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT barwicktarad discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT rockallandrea discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients
AT aboagyeerico discoveryofpretherapy2deoxy218ffluorodglucosepositronemissiontomographybasedradiomicsclassifiersofsurvivaloutcomeinnonsmallcelllungcancerpatients